Literature DB >> 3168326

Immunoregulatory properties of pulmonary surfactant: influence of variations in the phospholipid profile.

M L Wilsher1, D A Hughes, P L Haslam.   

Abstract

The aim of this study was to seek in vitro evidence to support our hypothesis that the immunosuppressive properties of pulmonary surfactant might be influenced by variations in phospholipid composition. Dose response studies conducted in serum-free medium, have demonstrated that pure phospholipids of the major types found in pulmonary surfactant, namely phosphatidylcholine (PC), phosphatidylglycerol (PG) and phosphatidylinositol (PI) exhibit significant dose dependent suppression of lymphocyte response to phytohaemagglutinin (PHA) (PC greater than PG greater than PI). By contrast, phosphatidylethanolamine (PE), sphingomyelin (SM), and the neutral lipid cholesterol (CH) augment the lymphoproliferative response in serum-free medium. The degree of suppression obtained using mixtures of various ratios of PC, PG and PI depended on the proportion of the most suppressive phospholipids (PC and PG). Similarly, increasing the proportion of PC in mixtures containing variable proportions of PE or CH resulted in increasing suppression of lymphoproliferation. Comparisons of the lipid fractions purified from pulmonary surfactant of three species (human, pig and rabbit) showed that the levels of suppression they induced reflected their relative content of phospholipids with the greatest immunosuppressive properties. We conclude that variations in phospholipid composition may affect the immunoregulatory properties of pulmonary surfactant.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168326      PMCID: PMC1541455     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Effect of LDL-In, a normal immunoregulatory human serum low density lipoprotein, on the interaction of macrophages with lymphocytes proliferating in response to mitogen and allogeneic stimulation.

Authors:  L K Curtiss; T S Edgington
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

3.  Inhibition of lymphocyte proliferation stimulated by lectins and allogeneic cells by normal plasma lipoproteins.

Authors:  J H Morse; L D Witte; D S Goodman
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

4.  Single plate separation of lung phospholipids including disaturated phosphatidylcholine.

Authors:  A M Gilfillan; A J Chu; D A Smart; S A Rooney
Journal:  J Lipid Res       Date:  1983-12       Impact factor: 5.922

5.  Enhancement of blastogenesis in cholesterol-enriched lymphocytes.

Authors:  S H Ip; J Abrahm; R A Cooper
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

6.  Peturbation of lymphocyte response to concanavalin A by exogenous cholesterol and lecithin.

Authors:  B Rivnay; A Globerson; M Shinitzky
Journal:  Eur J Immunol       Date:  1978-03       Impact factor: 5.532

7.  Bronchoalveolar lavage in patients with interstitial lung diseases: side effects and factors affecting fluid recovery.

Authors:  D P Dhillon; P L Haslam; P J Townsend; Z Primett; J V Collins; M Turner-Warwick
Journal:  Eur J Respir Dis       Date:  1986-05

8.  Phospholipids and microviscosity study in broncho-alveolar lavage fluids from control subjects and from patients with extrinsic allergic alveolitis.

Authors:  P Jouanel; C Motta; J Brun; C Molina; B Dastugue
Journal:  Clin Chim Acta       Date:  1981-09-10       Impact factor: 3.786

9.  Identification of the immunosuppressive components of canine pulmonary surface active material.

Authors:  M J Ansfield; B J Benson
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

10.  Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol.

Authors:  M Hallman; R Spragg; J H Harrell; K M Moser; L Gluck
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

  10 in total
  7 in total

1.  Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity.

Authors:  M L Wilsher; D A Hughes; P L Haslam
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

2.  Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains.

Authors:  Wondwossen Abate; Abdulaziz A Alghaithy; Joan Parton; Kenneth P Jones; Simon K Jackson
Journal:  J Lipid Res       Date:  2009-08-01       Impact factor: 5.922

3.  Immunogenicity of surfactant. I. Human alveolar surfactant.

Authors:  D S Strayer; M Hallman; T A Merritt
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

4.  Antigenic specificity and subset analysis of T cells isolated from the bronchoalveolar lavage and pleural effusion of patients with lung disease.

Authors:  A Faith; D M Schellenberg; A D Rees; D M Mitchell
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

5.  Early effects of short-time cigarette smoking on the human lung: a study of bronchoalveolar lavage fluids.

Authors:  N M Mancini; M C Béné; H Gérard; F Chabot; G Faure; J M Polu; O Lesur
Journal:  Lung       Date:  1993       Impact factor: 2.584

6.  Cholesterol as a Mediator of Alcohol-Induced Risks for Respiratory Disease Hospitalizations among People Living With HIV.

Authors:  María José Míguez; Rhonda Rosenberg; Ximena Burbano; Robert Malow
Journal:  J AIDS Clin Res       Date:  2011-10-21

7.  Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes.

Authors:  Markus Fehrholz; Kirsten Glaser; Silvia Seidenspinner; Barbara Ottensmeier; Tore Curstedt; Christian P Speer; Steffen Kunzmann
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.